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Background: Multiple sclerosis (MS), an autoimmune disease with neurodegeneration 
and inflammation is characterized by several alterations of different T cell subsets. 
However, few data exist on the role of iNKT lymphocytes.
Objective: To identify possible changes in the phenotype of iNKT cells in patients with 
different clinical forms of MS and find alterations in their polyfunctionality [i.e., ability 
to produce simultaneously up to four cytokines such as IL-17, tumor necrosis factor 
(TNF)-α, interferon (IFN)-γ, and IL-4].
Methods: We studied a total of 165 patients, 91 with a relapsing–remitting form 
[RR; 31 were treated with interferon (IFN)1a-β, 25 with natalizumab (NAT), 29 with 
glatiramer acetate; 17 were newly diagnosed RR without treatment, 19 not-active RR 
without treatment]. Forty-four patients had a progressive MS: 20 primary progressive 
(PP) and 24 secondary progressive (SP). A total of 55 age- and sex-matched subjects 
represented healthy controls (CTR). Among fresh peripheral blood mononuclear cells, 
iNKT cells were identified by flow cytometry. Moreover, the capability of iNKT cells to 
produce different cytokines (IL-17, TNF-α, IFN-γ, and IL-4) after in  vitro stimulation 
were evaluated in 18 RR (11 treated with NAT and 7 with IFN), 4 PP, 6 SP, and 16 CTR.
results: No main differences were found in iNKT cell phenotype among MS patients with 
different MS forms or during different treatments. However, the polyfunctional response 
of iNKT cells showed Th1 and Th17 profiles. This was well evident in patients with SP 
form, who are characterized by high levels of inflammation and neurodegeneration, and 
exhibited a sustained increase in the production of Th17 cytokines. Patients treated with 
NAT displayed lower levels of iNKT cells producing IL-17, TNF-α, and IFN-γ.
conclusion: Our data suggest that the progressive phase of the disease is character-
ized by permanent iNKT activation and a skewing towards an inflammatory phenotype. 
Compared to other treatments, NAT was able to modulate iNKT cell function.
Keywords: multiple sclerosis, inKT cells, cytokines, flow cytometry, immunomodulatory drugs
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inTrODUcTiOn
Multiple sclerosis (MS) is a chronic inflammatory and neuro-
degenerative disease of the central nervous system (CNS). The 
pathogenesis of MS is still unknown, but it is generally accepted 
that the alteration of autoimmune homeostasis plays a major role. 
The relationship between inflammation and neurodegeneration 
and their contribution to the different phases of the disease 
remains ambiguous (1). It is also unclear how these two processes 
are generated and controlled by different components of the 
immune system. Although adaptive immunity is clearly involved 
in the pathogenesis of MS, there is increasing evidence on the role 
of cells belonging to innate immunity (2).
iNKT cells belong to the family of innate-like lymphocytes; 
they are T lymphocytes characterized by the expression of 
NK cell markers and an invariant alpha chain and represent 
less than 1% of circulating T lymphocytes (3). iNKT cells are 
a specialized lymphocyte subset, which expresses an invariant 
Vα24Jα18 T-cell receptor and recognizes as cognate antigens 
self and foreign lipids presented by CD1d (4, 5). On the basis of 
CD4 and CD8 expression, mature iNKT cells can be divided into 
functionally distinct subsets, i.e., CD4+CD8−, CD4−CD8−, and 
CD4−CD8+ (3). iNKT cells mediate both protective and regula-
tory immune functions through a rapid production of cytokines 
(6). Indeed, activated iNKT cells can rapidly and simultaneously 
release large amounts of Th1 [interferon (IFN)-γ, tumor necrosis 
factor (TNF)-α] and Th2 cytokines [interleukin (IL)-4, IL-12, 
and IL-13] (7), and can also produce, under certain conditions, 
IL-10 (8) and Th17 cytokines such as IL-17 and IL-22 (9).
The aforementioned different subsets of iNKT cells have dif-
ferent immunological properties: CD4+ iNKT cells release Th1 
and Th2 cytokines, while CD8+ and CD4−, CD8− cells exhibit 
Th1 phenotypes and cytotoxic activity (10). Moreover, a regula-
tory phenotype of iNKT cells has also been described, based upon 
the production of IL-10 and transforming growth factor-beta, 
and on the expression of classical markers of regulatory T cells 
such as CD4, high expression of CD25, FoxP3, and the lack of 
CD127 (11). Of note is also that iNKT cells are able to produce 
granulocyte-macrophage colony-stimulating factor (12), which 
induces migration of human monocytes across the blood–brain 
barrier (13).
It has been suggested that iNKT cell defects can cause failure 
of immune regulation that predisposes an individual to autoim-
mune diseases (14–16). For example, the decreased frequency 
of iNKT cells in non-obese diabetic mice initially suggested the 
regulatory role of this cell subset (17). Similarly, in patients with 
systemic lupus erythematosus (SLE), the percentage of iNKT cells 
was lower than that of healthy subjects (18). In addition, many 
studies confirmed that NKT cells are characterized by reduced 
function and proliferative potential in rheumatoid arthritis (RA) 
and that cytokine production by NKT cells could depend from 
different backgrounds and at different stages of RA (19). Previous 
studies on iNKT cells in patients affected by MS showed the pres-
ence of different defects, but yielded contradictory results, mainly 
because of non-stringent methods used for the identification of 
iNKT cells that are quite rare in blood, and of the limited analysis 
of the distribution and/or function of their subsets (3, 20–22).
There is a general agreement that complex defects of innate 
cells exist in this pathology (3, 23), but the role of iNKT cell 
defects in MS has not been fully elucidated, and a detailed 
characterization of the phenotype and functionality of iNKT 
cells in the different forms of MS has never been reported. For 
these reasons, using the most advanced techniques based upon 
high-speed polychromatic acoustic flow cytometry, we evaluated 
the amount of these cells in patients with different forms of MS 
and during treatments with different immunomodulatory drugs. 
Moreover, we characterized iNKT phenotype and functional 
activities, i.e., the ability of different iNKT cell subsets of pro-
ducing cytokines, and we correlated immunological data with 
clinical parameters.
MaTerials anD MeThODs
Patient selection
Patients were selected at the “Center for Demyelinating Diseases” 
of the Neurology Unit of Modena (Nuovo Ospedale Civile S. 
Agostino Estense, Modena, Italy). Evaluation of entry criteria 
and subsequent enrollment in the study occurred during patients’ 
planned routine visits. Inclusion criteria were: age between 18 
and 65 years and diagnosis of MS according to the 2010 revised 
McDonald Criteria (24). Patients with concomitant infections 
(viral or bacterial), with a relapse treated with steroids in the 
preceding 30 days, and patients with non-steroidal anti-inflam-
matory drug intake within the preceding 48 h, were excluded.
A total of 165 MS patients were selected for the study:
 – 85 RR patients treated with disease-modifying drugs for at 
least 6  months: 31 with β-interferon 1a (IFN1a-β) 29 with 
glatiramer acetate (GA) and 25 with natalizumab (NAT);
 – 44 untreated patients with a progressive form of the disease: 20 
with PP, and 24 with secondary progressive (SP) form, without 
superimposed relapses in the preceding 2 years;
 – 17 newly diagnosed, untreated RR patients. This group was 
classified as “active” RR (ARR), following the 2013 revisions 
(25) of the previous MS phenotype descriptions. In particu-
lar, activity was determined by clinical relapses and/or MRI 
activity (contrast-enhancing lesions; new/enlarging lesions on 
T2-weighted images) in the preceding year;
 – 19 RR patients, untreated for at least 6  months prior to 
enrollment, and without clinical or MRI activity in the pre-
ceding 2 years. This group was classified as “not-active” RR 
(NARR) (25).
The functional analysis was carried out on 57 patients belong-
ing to the abovementioned groups, in particular: 13 RR patients 
treated with NAT, 11 with GA, 12 with IFN; 5 patients with not-
active RR, 4 with PP, 12 with SP, and 26 controls (CTR).
For each patient, the following parameters were recorded: 
demographic (sex, age), clinical [age at onset, disease duration, 
disability measured by Kurztke’s Expanded Disability Severity 
Score – EDSS (26), delta-EDSS in the preceding year, number 
of relapses in the preceding year, MS Severity Score – MSS (27), 
and MRI data (date of previous MRI assessment, number of 
 gadolinium-enhancing lesions, and/or new/enlarging T2 lesions)].
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Fifty-five sex- and age-matched healthy subjects, without 
a history of autoimmune diseases or immunosuppressant/
corticosteroid therapy, were chosen as controls. In order to 
avoid any potential effect of aging on iNKT cells, we divided 
controls in two groups: 39 younger controls (YCTR, mean 
age  ± SE  34.7  ±  1.1  years) and 16 older controls (OCTR, 
53.8 ± 1.5 years): YCTR were compared to ARR patients, while 
OCTR were compared to NARR and progressive patients who are 
older than RR patients.
The study obtained the Ethical Committee’s approval (no. 
246/12) of the province of Modena (Italy), and, at the time of 
enrollment, all individual participants included in the study signed 
the written informed consent in accordance with the Declaration 
of Helsinki. Table 1 summarizes MS patients’ characteristics.
isolation of Peripheral Blood Mononuclear 
cells and Polychromatic Flow cytometry
Thirty milliliters of venous blood were collected from each sub-
ject into ethylenediaminetetraacetic acid (EDTA) tubes. First, 
we performed the identification and enumeration of CD3+ 
T  lymphocytes in whole blood samples using the “CD3 easy 
count kit,” a kit with no lyse–no wash reagents for the volumetric 
absolute counting of CD3+ T cells, and the CyFlow Counter 
(Partec GmbH, Münster, Germany). Then, peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll–Hypaque 
density gradient according to standard procedures and immedi-
ately processed for immunophenotypic analysis.
Freshly isolated PBMCs were stained Aqua Live Dead Probe 
(Thermofisher) and with mAbs conjugated with the appropriate 
fluorochrome at previously defined optimal concentrations. The 
following mAbs were used: anti-Vα24JαQ TCR chain PE (clone 
6B11 was used because it reacts with a unique determinant in the 
CDR3 region of the invariant Vα24-JαQ TCR chain), anti-CD4 
APC-H7 (clone RPA-T4), anti-CD8 APC (clone RPA-T8), anti-
CD161 FITC (clone DX12), anti-CD3 PE-Cy7 (clone UCHT1) 
[all from Becton Dickinson Biosciences (BD), San José, CA, 
USA]; anti-CD19 ECD (clone J3-119) and anti-CD14 ECD 
(clone RMO52) (from Beckman Coulter Inc., Hialeah, FL, USA). 
PBMCs were incubated for 20 min at room temperature, washed 
with phosphate buffered saline, and immediately analyzed. 
A minimum of 10 million cells per sample were acquired and 
analyzed as described below.
In Vitro cytokine Production by inKT cells
For functional assays, freshly isolated PBMCs were stimulated for 
4 h at 37°C in a 5% CO2 atmosphere with phorbol 12-myristate 
13-acetate (PMA) (200 ng/mL, Sigma Aldrich, Saint Louis, MO, 
USA) plus ionomycin (1  mg/mL, Sigma-Aldrich), in complete 
culture medium (RPMI 1640 supplemented with 10% fetal 
bovine serum and 1% each of l-glutamine, sodium pyruvate, 
non-essential amino acids, antibiotics, 0.1  M HEPES, 55  μM 
β-mercaptoethanol). For each sample, at least 5 million cells 
were left unstimulated as negative control and at least 15 mil-
lion cells were stimulated. All samples were incubated with a 
protein transport inhibitor containing brefeldin A (Golgi Plug, 
BD). After 4 h of stimulation, cells were stained with live–dead 
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AQUA (Thermo Fisher Scientific) and surface mAbs recognizing 
Vα24JQ TCR chain PE, CD3 PE-Cy5, CD4 AF700, and CD8 
APC-Cy7 (Biolegend, San Diego, CA, USA). Cells were washed 
with stain buffer (BD) and fixed and permeabilized with the cyto-
fix/cytoperm buffer set (BD) for cytokine detection. Then, cells 
were stained with mAbs recognizing IL-17 BV421 (clone BL168), 
TNF-α BV603(clone MAb11), IFN-γ FITC (clone B27), or IL-4 
APC [clone 8D4-8 (all mAbs from Biolegend)], using previously 
described strategies for intracellular cytokine detection (28).
Up to 20 million cells per sample were acquired by an acoustic 
focusing flow cytometer (Attune NxT, Thermo Fisher Scientific, 
Eugene, OR, USA), equipped with four lasers for excitation at 
405, 488, 561, and 638 nm. We used the recently described the 
strategy required for the cytofluorimetric identification of rare 
events (24). Data were acquired in list mode using Attune NxT 2.1 
software, and analyzed by FlowJo 9.8.5 (Tree Star Inc., Ashland, 
OR, USA) under Mac OSX. Samples were compensated by soft-
ware, after acquisition. Single staining and fluorescence minus 
one (FMO) controls were performed for all mAbs of the panel to 
set proper compensation and define positive signals.
statistical analysis
Quantitative variables were compared with non-parametric 
Mann–Whitney U-test. The correlations between clinical 
parameters and molecular data were performed by Spearman 
Correlation test and linear regression analysis. A p Value <0.05 
was considered significant, except in case of multiple analyses, 
when the Bonferroni correction was applied. Data are repre-
sented as the mean ± SEM. Statistical analyses were performed 
using Prism 6.0 (Graphpad Software Inc., La Jolla, San Diego, 
CA, USA).
Simplified Presentation of Incredibly Complex Evaluation 
(SPICE) software (version 5.3, kindly provided by Dr. Mario 
Roederer, Vaccine Research Center, NIAID, NIH, Bethesda, MD, 
USA) was used to analyze polychromatic flow cytometry data, 
as described (29, 30). For the analysis of iNKT cell functionality, 
a threshold of 0.05% was set on the basis of the distribution of 
negative values (31, 32).
resUlTs
identification of inKT cells as rare events
In order to identify circulating iNKT whose percentage in 
peripheral blood is typically much less than 1%, it is mandatory 
to acquire a huge number of cells (28, 33). Thus, for the pheno-
typic and functional analysis, we made use of a novel acoustic 
flow cytometer able to align cells in the flow chamber by using 
ultrasounds and to acquire up to 35,000 events/second. This 
was crucial to obtain the number of cells, which is required for 
a correct statistical analysis, which was always >5 millions. The 
gating strategy used to identify iNKT cells with their subsets 
is shown in Figure  1, related to 22 million cells. Singlets were 
selected according to FSC-A and FSC-H, and the initial part 
of the acquisition was removed to avoid any possible instabil-
ity of the flux. A gate was set to identify living cells, i.e., those 
negative to the staining with the live–dead probe. Next, T cells 
were identified by positivity for CD3 expression and negativity 
for CD14 and CD19, markers included into the DUMP channel. 
iNKT cells were selected according to the presence of a Vα24-
JαQ TCR chain. On the basis of the expression of CD4 and CD8, 
different subsets of iNKT cells were identified: CD4+, CD8−, or 
CD4−, CD8+, or CD4−, CD8−. In all these subpopulations, the 
expression of CD161 was evaluated.
Phenotype of inKT changes in Different 
Forms and during Different Treatments of 
Multiple sclerosis
The percentage of T lymphocytes and their absolute number 
were similar among all groups of patients, but those treated with 
NAT showed a higher number of T lymphocytes if compared to 
other treated patients (data not shown). Similarly, the percentage 
and the absolute number of total iNKT cells were similar among 
different forms of MS (Figure 2A) or among RR patients treated 
with different immunomodulating therapies (Figure 2B).
As far as different subpopulations of iNKT cells are concerned, 
ARR patients and PP patients displayed higher levels of CD4+ 
iNKT cells if compared to their CTR group (Figure 2C). No differ-
ences were found among RR patients taking different treatments. 
SP patients displayed lower levels of CD4+ iNKT cells expressing 
CD161 if compared to not-active RR patients (Figure 2D), and 
higher levels of the same cell populations were found in RR patients 
treated with NAT (Figure 2E). Patients treated with IFN showed 
a reduction of CD4+ iNKT cells expressing CD161 (Figure 2F), 
even if the difference did not reach statistical significance.
cytokine Production by Different 
subsets of inKT cells
In order to study the polyfunctionality of iNKT cell subpopula-
tions, in a large set of experiments, we stimulated cells in vitro with a 
massive stimulus, represented by PMA plus ionomycin. However, 
before starting these experiments, we had analyzed polyfunction-
ality in iNKT cell lines, which were generated either from healthy 
donors or MS patients. We found that after a few weeks of culture 
in the presence of required stimuli such as high amounts of IL-2, 
autologous feeder layers and α-galactosylceramide (a synthetic 
glycolipid derived from a marine sponge that is the most efficient 
compound for activating the majority of NKT cells), all cells, 
both from patients and controls, presented the same phenotype, 
i.e., >50% DN, about 33% CD8+, and few CD4+; almost all cells 
were CD161++. For this reason, we chose to analyze phenotypic 
and functional changes after a short period of incubation, i.e., 4 h 
of stimulation being well aware that PMA plus ionomycin was a 
massive stimulus, also able to induce cell death (in all samples, we 
used a viability marker to eliminate dead cells from the analysis).
In a representative group of MS patients and healthy subjects, 
we could investigate the ability of iNKT cells to produce different 
cytokines by using intracellular staining and acoustic flow cytom-
etry. Since, in this set of analyses, the age of patients and healthy 
subjects was matched, we used one group of control donors. The 
strategy to identify the production of up to four cytokines by 
different subsets of iNKT cells after 4-h stimulation is shown in 
Figure 3. Doublets and fluorochrome aggregates were removed 
FigUre 1 | gating strategy to identify inKT cells expressing cD4, or cD8, or double negative (Dn) cells. A first gate was set on FCS-height vs. FCS-area 
to eliminate doublets and aggregates, the on “time of acquisition,” then, on living cell, according to negativity to live–dead staining. CD3+ T lymphocytes were 
identified after the removal of monocytes (CD14+) and B cells (CD19+), recognized in the DUMP channel. Then, iNKT cells were recognized according the positivity 
to Vα24-JαQ TCR chain. Finally, CD4+, CD8+, or CD4−, CD8− double negative (DN) iNKT were identified. In all these subsets, the expression of CD161 was 
evaluated. Seven color flow cytometry was used, and a minimum of 10 million events per sample were acquired using Attune NxT flow cytometer.
5
De Biasi et al. iNKT Cells in Multiple Sclerosis
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 555
FigUre 2 | Percentages of inKT cells and their subpopulations among the different groups of Ms patients and controls. (a) Percentage of iNKT cells 
among patients with different multiple sclerosis form; (B) percentage of iNKT cells among RR patients treated with different immunomodulatory drugs; (c) 
percentage of CD4+ iNKT cells among patients with different multiple sclerosis forms; (D) percentage of CD4+ iNKT cells among RR patients treated with different 
immu nomodulatory drugs; (e) percentage of CD4+ iNKT cells expressing CD161+ among patients with different multiple sclerosis forms; (F) percentage of CD4+ 
iNKT expressing CD161 cells among RR patients treated with different immunomodulatory drugs. ARR, active relapsing–remitting; NARR, untreated patients with 
not-active RR; PP, untreated primary progressive; SP, secondary progressive; GLA: RR patients who had been treated for at least 6 months with either glatiramer 
acetate (GLA), or with beta-interferon-1a (IFN) or with natalizumab (NAT). YCTR: donors whose age was <46 years; OCRT: controls >46 years. Quantitative 
variables were compared with non-parametric Mann–Whitney U-test. *p Values <0.05 were considered statistically significant. Data are represented as the 
mean ± SEM.
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by electronic gates, and living T lymphocytes were identified on 
the basis of the expression of CD3 and negativity for live–dead 
probe, and then iNKT cells expressing CD4 or CD8 were recog-
nized. In each subset defined by CD4 or CD8 expression, or in 
double negative (DN) cells, the intracellular presence of TNF-α, 
IFN-γ, IL-4, or IL-17 was identified.
We could measure both the “total” response, that is, the sum of 
all cells positive for at least one marker (this provides the overall 
frequency of responding cells) and the “qualitative” response, 
which describes the contribution of each functional pattern to 
the total specific response. Surprisingly, we pointed out that 
iNKT cells of patients and controls did not display any significant 
polyfunctionality feature except for the co-production of IFN-γ 
and TNF-α among CD4−CD8− iNKT cells of RR patients treated 
with different therapies. Cells were characterized by the predomi-
nant expression of Th1 and Th17 cytokines that, however, was not 
simultaneous to that of other molecules. For this reason, we refer 
to the total production of each cytokine.
among Untreated Patients, sP Patients 
Displayed higher levels of inKT cells 
able to Produce il-17
The percentage of not responding CD4+ iNKT cells after stimulus 
was similar among different forms of MS patients and controls, 
and was approximately 70% (Figure 4A). The remaining 30% of 
FigUre 3 | gating strategy for the identification of the polyfunctionality of different subpopulations of inKT cells. Several electronic gates were set, first 
to exclude doublets on the basis of physical parameters (forward scatter area and height), then to exclude dead cells and to identify CD3+ T lymphocytes, and 
finally to recognize iNKT cells and their subpopulations, on the basis of CD4 and CD8 expression. Among these subpopulations, the production of IL-4, IL-17, 
TNF-α, and IFN-γ is quantified. Nine-color flow cytometry was used, acquiring a minimum of 10 million events per sample.
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FigUre 4 | cytokine production by different subpopulations of inKT cells after stimulation. (a) Percentage of CD4+ iNKT cells that did not produce any 
cytokine after in vitro stimulation (not responding); (B) total IL-17 production by CD4+ iNKT cells; (c) total TNF-α production by CD4+ iNKT cells; (D) total IFN-γ 
production by CD4+ iNKT cells; (e) percentage of not responding CD8+ iNKT cells; (F) total IL-17 production by CD8+ iNKT cells; (g) total TNF-α production by 
CD8+ iNKT cells; (h) total IFN-γ production by CD8+ iNKT cells. The functional analysis was carried out on: 5 patients with not-active RR, 4 with PP, 12 with SP 
and 26 CTR. Bar graphs indicate mean ± SEM; *p < 0.05.
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iNKT cells expressing CD4 were able to produce Th1 and Th17 
cytokines. In particular, SP patients displayed higher levels of 
CD4+ iNKT cells producing IL-17 if compared to CTR and to PP 
patients (Figure 4B). NARR patients displayed a higher percent-
age of CD4+ iNKT cells producing TNF-α if compared to CTR 
(Figure 4C). No differences were found in the percentage of cells 
producing IFN-γ (Figure 4D).
The percentage of CD8+ iNKT cells able to produce 
cytokines after in  vitro stimulation was similar in all forms of 
MS (Figure  4E). However, progressive patients (both PP and 
SP) were characterized by higher levels of CD8+ iNKT cells that 
produced IL-17 if compared to controls, while NARR patients 
displayed lower percentages of these cells, even when compared 
to controls (Figure 4F). Moreover, NARR patients showed high 
levels of CD8+ iNKT cells, able to produce TNF-α if compared 
to controls (Figure 4G), while also in the case of CD8+ T cells, 
no differences among groups were found in the production of 
IFN-γ (Figure 4H).
natalizumab Turns Off Pro-inflammatory 
cytokine Production by inKT cells
Last, we investigated the modulatory effects of different immu-
nomodulatory treatments on cytokine production by iNKT cells 
in patients treated with GA, IFN, or NAT for at least 6 months. 
The overall percentage of CD4+ iNKT cells responding to a 
potent stimulation was similar in all the groups (Figure  5A). 
However, patients treated with NAT displayed lower levels of 
CD4+ iNKT cells producing IL-17 if compared to all other 
treatments (Figure  5B), along with lower levels of TNF-α 
(Figure  5C). No differences were found in the production of 
IFN-γ (Figure 5D).
Nearly, 80% of CD8+ iNKT of patients treated with NAT 
did not respond to the in  vitro stimulation, a percentage that 
was higher than that found in patients treated with GA or IFN 
(Figure  5E). Accordingly, patients treated with NAT displayed 
the lowest percentage of CD8+ iNKT cells able to produce IL-17 
(Figure 5F), TNF-α (Figure 5G), and IFN-γ (Figure 5H).
As far as DN CD4−, CD8− iNKT cells are concerned, patients 
treated with NAT showed the highest percentage of cells unable 
to produce cytokines (Figure 5I). They also displayed the lowest 
percentage of cells able to produce IL-17 (Figure  5J), TNF-α 
(Figure  5K), and IFN-γ (Figure  5L). Considering the poly-
functionality of these cells, we found that DN iNKT cells able to 
produce IFN-γ and TNF-α, but not IL-4 or IL-17, were decreased 
in patients treated with NAT (Figure  5M). Using the software 
SPICE, no significant changes were noted as far as other combina-
tions are concerned (not shown).
DiscUssiOn
changes in inKT cell subsets
In the field of immune-mediated diseases, the importance of 
iNKT cells was first recognized through the observation that 
mice lacking CD1d or iNKT cells were predisposed to develop 
several autoimmune diseases (34), but few data are present as far 
as the role of iNKT cells in the pathogenesis of MS is concerned. 
Thus, the purpose of the present study was to finely analyze the 
phenotypic and functional characteristics of peripheral iNKT 
cells in 165 MS patients compared to 55 healthy subjects.
No significant differences were found in the overall percentage 
and in the absolute number of total iNKT cells in patients with 
different forms of MS; nevertheless, significant changes took place 
among different iNKT cell subpopulations. Moreover, functional 
differences not only among patients with different MS forms but 
also among those treated with different disease-modifying drugs 
(DMDs) have been detected.
Previous studies reported that MS patients showed 
decreases (20, 35) or increases in the number of iNKT cells 
(15) compared to controls, while no clear differences between 
MS patients and controls have been found in the present study. 
These discrepancies could be due to several reasons, includ-
ing the different panels of monoclonal antibodies used for the 
flow cytometric analysis and the use of different strategies for 
their identification. In fact, our approach was based upon the 
strategy of detection of rare cells: we analyzed a minimum of 
ten million events per sample and used fresh blood, against 
100,000–200,000 events acquired in previous studies. Moreover, 
previous studies enrolled small cohorts of patients, while our 
study not only included a much higher number of patients but 
patient groups were also more homogeneous, since we carefully 
considered patients’ disease activity profile, treatment regimen, 
and age.
We found that, in RR patients, the percentage of iNKT cells 
was not affected by DMDs. A previous study reported that treat-
ment with IFN significantly increased the percentage of periph-
eral Vα24+ T cells (36). However, the cohort of IFN-treated and 
untreated patients was relatively small (eight treated vs. four 
non-treated patients).
Regarding different iNKT cell subsets, in the present study, 
ARR patients and PP patients showed a higher percentage of 
iNKT cells expressing CD4+ compared to controls. SP patients 
showed the same trend, even though statistical significance was 
not reached. These findings suggest that the active phase of MS, 
as well as its progression, seems to be characterized by a sus-
tained presence of CD4+ iNKT cells, which probably contribute 
to the presence and/or to the persistence of an inflammatory 
status.
We found that NARR patients displayed a higher percent-
age of CD4+ iNKT cells expressing CD161 if compared to SP 
patients. Even though the meaning of CD161 expression by 
iNKT cells remains to be fully elucidated, it is widely accepted 
that CD161 is involved in the regulation of NKT cell function 
and, indeed, triggering of CD161 enhances NKT cell proliferation 
(37). Furthermore, the expression of CD161 is associated with 
cells expressing a memory phenotype and has been related to the 
secretion of IL-17, a potent pro-inflammatory cytokine with a 
recently reported role in progressive MS patients (38).
Functional characteristics of inKT cells
We found that iNKT cells from patients with different forms 
of MS were able to respond to a potent stimulation, and they 
mainly produced Th1 and Th17 cytokines, such as TNF-α, IFN-γ, 
and IL-17. Previous studies regarding such cells in RR patients 
FigUre 5 | cytokine production by different subpopulations of inKT cells in rr patients treated with different immunomodulatory drugs.
(Continued)
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FigUre 5 | continued  
(a) Percentage of CD4+ iNKT cells not responding after in vitro stimulation; (B) total IL-17 production by CD4+ iNKT cells; (c) total TNF-α production by CD4+ 
iNKT cells; (D) total IFN-γ production by CD4+ iNKT cells; (e) percentage of not responding CD8+ iNKT cells; (F) total IL-17 production by CD8+ iNKT cells; 
(g) total TNF-α production by CD8+ iNKT cells; (h) total IFN-γ production by CD8+ iNKT cells; (i) percentage of not responding CD4−CD8− iNKT cells; (J) total 
IL-17 production by CD4−CD8− iNKT cells; (K) total TNF-α production by CD4−CD8− iNKT cells; (l) total IFN-γ production by CD4−CD8− iNKT cells; 
(M) polyfunctionality of CD4−CD8− iNKT cells after in vitro stimulation. Bar graphs indicate mean ± SEM; *p < 0.05; **p < 0.01. The functional analysis was carried 
out on: 13 RR patients treated with NAT, 11 with GA, and 12 with IFN.
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showed that patients with “inactive” MS, compared with those 
during a clinical relapse, exhibit a prevailing Th2 phenotype, 
indicating indirectly that this immunosuppressive phenotype 
could be absent in patients who are in the active phase of the 
disease (35). Our data on the functionality of these cells, in 
particular on CD4+ iNKT cells producing IL-17, support this 
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hypothesis, and suggest that this phenotype could be related 
with inflammation in active and progressive disease.
Interestingly, iNKT cells were not polyfunctional in most 
cases. SP patients displayed a Th17 pattern of cytokine produc-
tion and a higher percentage of CD4+ iNKT cells producing 
IL-17 compared to controls. Furthermore, progressive patients 
(both PP or SP), who displayed higher levels of CD4+ iNKT cells 
showed higher amounts of CD4+ iNKT cells able to produce 
TNF-α.
A close association between inflammation and neurodegen-
eration has been reported in all disease stages of MS (39, 40), 
and the extent of axonal injury appears to be related with the 
degree of inflammation (41) and of disability accumulation. Our 
results in the progressive forms of MS support the hypothesis 
of a pathogenetic role of inflammation in the development of 
disease progression. Many previous studies reported increased 
activation of peripheral blood immune cells from progressive 
patients, while pathology studies indicate that in SP and PP the 
inflammation is abundant, widespread and diffuse in CNS, and 
correlates with axonal damage and disease progression (42). 
A crucial role of IL-17 and of dysregulation of the IL-23/IL-17 
axis in the blood of SP patients, and a correlation between the 
levels of these pro-inflammatory factors, the lesion load at MRI 
and brain atrophy have been recently documented (43, 44). 
Studies in experimental autoimmune encephalitis animal models 
showed that myelin-reactive Th17 cells induces ectopic follicles 
in the CNS (45), and this seems particularly intriguing in light of 
the discovery of lymphoid follicle-like structures in the meninges 
and in the large perivascular space of CNS of SP patients’ brain 
specimens, supporting the hypothesis of a compartmentalization 
of, and sustained inflammation in the CNS of progressive stages 
of MS (46, 47). Our data on iNKT cells in SP-MS patients sup-
port the hypothesis that Th17 responses play a crucial role in the 
development of the progressive phases of MS (44, 48, 49) maybe, 
in part, via activation of iNKT cells, and the production of Th1 
and Th17 cytokines.
DMDs influence inKT cells
Regarding RR patients treated with DMDs, those treated with 
NAT displayed a higher, but not significantly so, percentage of 
CD4+ iNKT cells expressing CD161, a lower production of IL-17 
and TNF-α by both CD4+ and CD8+ iNKT cells, compared to 
patients treated with IFN.
The immunological effects of NAT, one of the latest and most 
effective therapies (50), on peripheral blood cells of RR patients 
are still unclear. NAT acts as an antagonist of the receptor 
VLA-4 beta-integrin by inhibiting the transmigration of auto-
reactive B and T lymphocytes into the CNS (51). Likely, this 
is not the only biological action of the drug. According to the 
AFFIRM trial, in RR patients, treatment with NAT reduced the 
annualized relapse rate by 68% compared to placebo, caused a 
42% reduction of sustained disability progression over 2 years, 
and had a strong therapeutic effect on MRI disease activity 
(83% of reduction of new T2 lesions and contrast-enhancing 
lesions) (52).
Recent studies suggest that NAT induces changes in the 
phenotype of lymphocytes, which may be caused by direct 
induction of intracellular signaling events and seem to induce 
a mild upregulation of pro-inflammatory phenotypes in some 
patients, without modifying regulatory T cell function (53–55). 
The changes in the Th1/Th2 paradigm cannot, however, explain 
the beneficial effect of NAT, and it was suggested that it might be 
linked to the blockade of migration in the CNS and to the sub-
sequent accumulation of activated lymphocytes in the periphery 
during exposure to the drug.
All these studies have, however, several limitations, including 
very small patient numbers and different timing of cytokines 
measurements. To date, to our knowledge, no other studies have 
focused on peripheral iNKT cells of MS patients treated with 
NAT. The possible role of cytokine profile changes induced by 
NAT treatment remains largely controversial and requires further 
investigation. In any case, our results on the polyfunctionality 
of iNKT cells indicate that NAT seems to inhibit their pro-
inflammatory action.
cOnclUsiOn
This study has characterized iNKT phenotype and functional 
activities in different forms of MS and during treatment with 
different DMDs. Our results indicate that the SP form is charac-
terized by activation of iNKT cells in the peripheral blood, which 
are skewed toward the production of Th1 and Th17 cytokines, 
supporting an important role of inflammation also in the progres-
sive phases of the disease. Moreover, we suggest that DMDs seem 
to modulate iNKT cell function.
No gross differences in iNKT percentages or in their number 
have been found in the different forms of disease or in response 
to different therapies. The more important findings were related 
to the function of these cells and to their ability of modulating 
and impacting cytokine homeostasis. Recent data indicate that 
iNKT cells differentiating out of the intestine do not produce 
IFN-γ (56), and that, in general, the production of cytokines 
by iNKT cells is governed by their localization (57). Moreover, 
cytokine and cell profiles in the periphery may differ, and be 
even opposite, to those in the CNS. To date, there is no data 
on the behavior of such cells in the context of the CNS. Further 
studies are, thus, needed to examine whether the iNKT-cell 
pro-inflammatory profile is present in different tissues and 
organs of MS patients, and whether these cells may exert a 
harmful effect.
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